Advertisement OXiGENE gets European patent for OXi4503 in AML and other myeloid malignancies - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

OXiGENE gets European patent for OXi4503 in AML and other myeloid malignancies

OXiGENE, a biopharmaceutical company developing novel cancer therapeutics, announced that the company has been granted a patent by the European Patent Office related to its current clinical product candidate, OXi4503.

The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML).

"We are pleased to be granted this additional patent for OXi4503 in Europe, which builds on similar patents recently issued in Australia and Japan, and further extends the patent protection for this novel therapeutic candidate," said Dai Chaplin, Ph.D., OXiGENE’s President and CEO.

"AML is an area of significant unmet need, and we are highly encouraged by the preclinical and early clinical data to date that support the ongoing development of OXi4503 as a potential new option for patients."

OXi4503 (combretastatin A1 di-phosphate) is a dual mechanism vascular disrupting agent that has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis.

Patients with relapsed and refractory AML or myelodysplastic syndrome (MDS) are currently receiving OXi4503 in a Phase 1 investigator-sponsored study.

The study is sponsored in part by The Leukemia & Lymphoma Society’s Therapy Acceleration Program, and is being conducted by researchers at the University of Florida.